Elicio Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging -6.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.53 | $-0.43 | +18.9% | Beat | |
| Q1 FY26 | $-0.49 | $-0.65 | -32.6% | Miss | |
| Q4 FY25 | $-0.47 | $-0.49 | -4.3% | Miss |
Back to ELTX overview · ELTX holders · ELTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.